Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

NCT01520389 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Colorectal Cancer
Squamous Cell Head and Neck Cancer
Non Small Cell Lung Cancer
Triple Negative Breast Cancer

Interventions

DRUG: MM-151
DRUG: MM-151 + irinotecan

Sponsor

Merrimack Pharmaceuticals